Related Image: Chronic exposure to estrogen impairs some cognitive functions |
(Date:11/5/2009)...ining grant in the amount of $2,756,719 by the Nat...duation Education and Research Training (IGERT) pr... to Kent State. The grant, which is funded under t... runs through 2014. , The grant funds an IGERT p...e sensing (EARS). The purpose of the program is to...
(Date:11/4/2009)...g Beach and Riverside are responsible for a signif...and the true impact of air pollution and ship emis...d, according to researchers at the University of S...pears in an online edition of the American Journa...f all childhood asthma cases in Long Beach and six...
(Date:11/4/2009)... DNA codes, or genomes, of the famed fugu (or puff...10K Project, an international effort to build an i...ecies of animals for conducting comparative studie..., Participating in The Genome 10K project, descri... of the Journal of Heredity , are 70 leading scie...
Breaking Biology News(10 mins):Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2USC study finds big air pollution impacts on local communities 2Singapore scientists join international study of 10,000 vertebrates' genomes 2Radiology Benefit Management Could Save Medicare up to 2418 Billion Over 10 Years 51941 1Radiology Benefit Management Could Save Medicare up to 2418 Billion Over 10 Years 51941 2Radiology Benefit Management Could Save Medicare up to 2418 Billion Over 10 Years 51941 3Scientists Reverse Muscular Dystrophy in Mice 51938 1Scientists Reverse Muscular Dystrophy in Mice 51938 2Scientists Reverse Muscular Dystrophy in Mice 51938 3Arcadian Chairman and Chief Executive Officer Robert Fahlman to Present at Focus on Healthcare Conference in New York City 51935 1(Date:11/5/2009)...DOVA, Calif., Nov. 5 The...ier of innovative products for processing and stor...he first quarter of fiscal 2010. ,, For the qua...d revenues of $5.2 million, a 15 percent increase ... a year ago. The Company said the key contributors...
(Date:11/5/2009)...., Nov. 5 Transgenomic, ...nancial results for the quarter ended September 30...ted in the tables that follow. ,, Third Quarte...366,000 or $0.01 per share for the third quarter o....01 per share for the third quarter of 2008. ,...
(Date:11/5/2009)... Calif., Nov. 5 Cepheid ...es will be speaking at the following investor conf...webcast. , , Credit Suisse Healthc...day, 12 November, 2009 at 10 a.m. Mountain Time, ...London, England, Tuesday, 1 Decemb...
(Date:11/5/2009)... CA, November 5, 2009 Se... using proprietary taste receptor-based technologi...od, beverage, and ingredient supply industries, to...cial results for the third quarter ended September...rd quarter of 2009, compared to $4.0 million for t...
Breaking Biology Technology:ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7Cepheid to Webcast Upcoming Financial Presentations 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14...IN LAKES, N.J., March 13 Medco Health,Solutions, ...eed to sell $300,million aggregate principal amoun... and $1.2 billion aggregate principal amount of 7-...underwritten public offering. Citi,J.P. Morgan Sec...arclays,Capital Inc. are acting as representatives...
... Generation Treatment from Abbott Shows No Thrombo...ary Clinical Study of Thirty Patients, ABBOTT PAR...cet from ABSORB, the world,s first clinical trial ...e treatment of coronary artery,disease, demonstrat...t,lesion revascularizations (retreatment of a dise...
...EY, Calif., March 13 Nile Therapeutics,Inc. (OTC ...quarter and,full year financial results for 2007. ...e conference call from the investor relations sect... . The webcast will remain available on,the compan...ll., For the fourth quarter of 2007, Nile reporte...
Other Biology Technology:Medco Issues $1.5 Billion of Senior Notes 2Medco Issues $1.5 Billion of Senior Notes 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3Luminex 100 IS System from Luminex Corporation
GIBCO Water distilled from Invitrogen
Rabbit Anti-Bovine Respiratory Syncytial Virus Bovine Respiratory Syncytial Virus Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-MacMarcks Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Biology Products: